Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). The only report of Serum Sickness (SS) in a MS patient occurred during treatment with natalizumab. Non-protein drugs, such as some antibiotics, may induce “SS-like” reactions (SSLR), whose clinical and laboratory features may partially overlap with the traditional SS. Objective: To report a case of SS/SSLR in a RRMS patient treated with alemtuzumab. Case report: A 42-year-old-woman with RRMS developed SS/SSLR in the first week after the first alemtuzumab treatment. Concomitant medications included trimethoprim-sulfamethoxazole at low dose. Intravenous methylprednisolone therapy led to clinical resolution and normalization of serum inflammatory markers. Conclusion: SS/SSLR should be considered in patients treated with alemtuzumab developing delayed fever, rash and arthralgia and differentiated with Infusion Associated Reactions (IARs) and infections.

Original languageEnglish
Pages (from-to)52-54
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume26
DOIs
Publication statusPublished - Nov 1 2018

Keywords

  • Alemtuzumab
  • Arthralgia
  • Monoclonal antibodies
  • Multiple Sclerosis
  • Serum sickness
  • Serum sickness like reaction

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report'. Together they form a unique fingerprint.

Cite this